Eichinger S, Pabinger I, Hartl H, Stain C, Mayerhofer S, Schweiger C, Kier P, Schwarzinger I, Kyrle P A, Lechner K
First Department of Medicine, University of Vienna, Austria.
Thromb Haemost. 1990 Aug 13;64(1):108-12.
Twenty-one immunodeficiency virus 1 (HIV 1)-positive hemophilic patients were treated with Azidothymidine (AZT) for symptomatic HIV infection. The median observation period was 20.5 months. At 25 months the probability of survival was 82%, the probability of progression of disease from CDC III or IV C2 to IV C1 (AIDS) was 20% in patients on continuous AZT treatment and 50% in patients with interruption of treatment. Three patients developed severe leukopenia and 3 patients severe anemia during AZT treatment. In 1 patient a dose-dependent striking increase of transaminases during AZT treatment was observed. In 7 patients treatment was interrupted, in 1 patient because of anemia, in 1 because of pruritus and in 5 patients because of non-compliance. No significant changes in the consumption of clotting factor concentrates and number of bleeding episodes before and during AZT treatment were noted. We conclude, that both hematological and non-hematological side effects of AZT in HIV 1-infected hemophilic patients are comparable to those seen in other risk groups. AZT does not increase the bleeding tendency in this patient group.
21例1型免疫缺陷病毒（HIV-1）阳性的血友病患者因有症状的HIV感染接受了齐多夫定（AZT）治疗。中位观察期为20.5个月。在25个月时，存活概率为82%，接受持续AZT治疗的患者疾病从疾病控制与预防中心（CDC）III或IV C2期进展至IV C1期（获得性免疫缺陷综合征，AIDS）的概率为20%，治疗中断的患者这一概率为50%。3例患者在AZT治疗期间出现严重白细胞减少，3例出现严重贫血。1例患者在AZT治疗期间观察到转氨酶呈剂量依赖性显著升高。7例患者中断治疗，1例因贫血，1例因瘙痒，5例因不依从。未发现AZT治疗前和治疗期间凝血因子浓缩物用量及出血发作次数有显著变化。我们得出结论，AZT在HIV-1感染的血友病患者中的血液学和非血液学副作用与在其他风险组中所见相当。AZT不会增加该患者组的出血倾向。
